| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 37 | 2025 | 479 | 5.700 |
Why?
|
| Neoplasms | 40 | 2025 | 1341 | 5.640 |
Why?
|
| Exercise | 21 | 2025 | 674 | 4.030 |
Why?
|
| Quality of Life | 16 | 2024 | 599 | 3.180 |
Why?
|
| Exercise Therapy | 15 | 2025 | 83 | 2.930 |
Why?
|
| Ovarian Neoplasms | 27 | 2023 | 406 | 2.880 |
Why?
|
| Survivors | 15 | 2023 | 152 | 2.420 |
Why?
|
| Indians, North American | 6 | 2022 | 179 | 2.310 |
Why?
|
| Fatigue | 9 | 2022 | 97 | 1.990 |
Why?
|
| Middle Aged | 76 | 2025 | 11819 | 1.880 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 9 | 2024 | 130 | 1.690 |
Why?
|
| Aged | 56 | 2025 | 7982 | 1.630 |
Why?
|
| Genetic Predisposition to Disease | 19 | 2025 | 727 | 1.630 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2020 | 164 | 1.620 |
Why?
|
| Humans | 138 | 2025 | 42163 | 1.560 |
Why?
|
| Female | 95 | 2025 | 24018 | 1.520 |
Why?
|
| Resistance Training | 5 | 2015 | 20 | 1.500 |
Why?
|
| Case-Control Studies | 36 | 2025 | 1266 | 1.260 |
Why?
|
| Health Promotion | 5 | 2023 | 691 | 1.250 |
Why?
|
| Genome-Wide Association Study | 17 | 2025 | 421 | 1.240 |
Why?
|
| Smoking | 16 | 2024 | 1019 | 1.230 |
Why?
|
| Risk Factors | 39 | 2025 | 3942 | 1.200 |
Why?
|
| Muscle Strength | 4 | 2015 | 36 | 1.170 |
Why?
|
| Male | 57 | 2025 | 22779 | 1.120 |
Why?
|
| Breast Neoplasms | 9 | 2024 | 1679 | 1.080 |
Why?
|
| Adult | 47 | 2025 | 13458 | 1.030 |
Why?
|
| Polymorphism, Single Nucleotide | 16 | 2025 | 860 | 0.950 |
Why?
|
| Reproductive History | 3 | 2017 | 27 | 0.720 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2021 | 21 | 0.720 |
Why?
|
| Focus Groups | 2 | 2022 | 398 | 0.710 |
Why?
|
| Medical Oncology | 6 | 2025 | 46 | 0.700 |
Why?
|
| Athletic Injuries | 1 | 2021 | 25 | 0.690 |
Why?
|
| Sports | 1 | 2021 | 53 | 0.670 |
Why?
|
| Aged, 80 and over | 14 | 2019 | 2803 | 0.650 |
Why?
|
| Employment | 1 | 2020 | 83 | 0.640 |
Why?
|
| Community-Based Participatory Research | 4 | 2019 | 336 | 0.630 |
Why?
|
| Young Adult | 19 | 2025 | 4936 | 0.630 |
Why?
|
| Immunity | 1 | 2019 | 60 | 0.620 |
Why?
|
| Women's Health | 3 | 2020 | 158 | 0.610 |
Why?
|
| Neoplasms, Glandular and Epithelial | 5 | 2017 | 57 | 0.610 |
Why?
|
| Treatment Outcome | 10 | 2022 | 1586 | 0.600 |
Why?
|
| Interleukins | 1 | 2018 | 37 | 0.590 |
Why?
|
| Postmenopause | 3 | 2020 | 139 | 0.590 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 143 | 0.590 |
Why?
|
| Cost of Illness | 1 | 2019 | 95 | 0.590 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 53 | 0.580 |
Why?
|
| Michigan | 6 | 2025 | 52 | 0.550 |
Why?
|
| Patients | 1 | 2017 | 16 | 0.550 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 428 | 0.540 |
Why?
|
| United States | 27 | 2025 | 5072 | 0.530 |
Why?
|
| Bone Density | 3 | 2012 | 102 | 0.520 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2025 | 187 | 0.500 |
Why?
|
| Pancreatic Neoplasms | 5 | 2021 | 206 | 0.490 |
Why?
|
| Confidentiality | 1 | 2016 | 27 | 0.490 |
Why?
|
| Exercise Tolerance | 2 | 2019 | 22 | 0.490 |
Why?
|
| Information Dissemination | 1 | 2016 | 66 | 0.480 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2015 | 14 | 0.470 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 42 | 0.470 |
Why?
|
| Data Collection | 1 | 2016 | 210 | 0.460 |
Why?
|
| Community-Institutional Relations | 2 | 2018 | 208 | 0.460 |
Why?
|
| Cooperative Behavior | 2 | 2018 | 250 | 0.460 |
Why?
|
| Rest | 1 | 2015 | 33 | 0.450 |
Why?
|
| Neoplasm Staging | 8 | 2019 | 366 | 0.450 |
Why?
|
| Cohort Studies | 9 | 2024 | 1729 | 0.450 |
Why?
|
| Odds Ratio | 15 | 2019 | 587 | 0.430 |
Why?
|
| Physical Therapy Modalities | 1 | 2015 | 47 | 0.430 |
Why?
|
| Motor Activity | 3 | 2016 | 438 | 0.410 |
Why?
|
| Pilot Projects | 5 | 2025 | 733 | 0.410 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 471 | 0.400 |
Why?
|
| Prognosis | 9 | 2021 | 850 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2019 | 14 | 0.390 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 680 | 0.380 |
Why?
|
| Adenocarcinoma | 4 | 2018 | 287 | 0.370 |
Why?
|
| Germ-Line Mutation | 4 | 2016 | 74 | 0.370 |
Why?
|
| Hip Fractures | 1 | 2012 | 29 | 0.370 |
Why?
|
| Osteoporosis | 1 | 2012 | 48 | 0.360 |
Why?
|
| Hand Strength | 1 | 2011 | 39 | 0.360 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 225 | 0.350 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2011 | 21 | 0.350 |
Why?
|
| Healthcare Disparities | 3 | 2025 | 573 | 0.340 |
Why?
|
| Genetic Variation | 5 | 2021 | 429 | 0.340 |
Why?
|
| Body Mass Index | 8 | 2024 | 916 | 0.340 |
Why?
|
| Carcinoma | 3 | 2016 | 106 | 0.330 |
Why?
|
| Signal Transduction | 1 | 2018 | 2111 | 0.310 |
Why?
|
| Aging | 3 | 2025 | 764 | 0.300 |
Why?
|
| Diet | 4 | 2023 | 810 | 0.280 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2019 | 6 | 0.280 |
Why?
|
| Receptors, Nicotinic | 4 | 2016 | 114 | 0.280 |
Why?
|
| Prospective Studies | 4 | 2023 | 1574 | 0.280 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2019 | 44 | 0.270 |
Why?
|
| Recreation | 2 | 2017 | 42 | 0.260 |
Why?
|
| Methylphenidate | 2 | 2009 | 56 | 0.260 |
Why?
|
| Telomerase | 2 | 2019 | 42 | 0.260 |
Why?
|
| Arizona | 2 | 2018 | 118 | 0.260 |
Why?
|
| Genome, Human | 3 | 2021 | 143 | 0.250 |
Why?
|
| Qualitative Research | 2 | 2020 | 526 | 0.250 |
Why?
|
| Mosaicism | 2 | 2016 | 7 | 0.240 |
Why?
|
| Physical Fitness | 2 | 2019 | 93 | 0.240 |
Why?
|
| Program Evaluation | 3 | 2022 | 358 | 0.240 |
Why?
|
| Genetic Research | 1 | 2025 | 11 | 0.230 |
Why?
|
| Central Nervous System Stimulants | 2 | 2009 | 181 | 0.230 |
Why?
|
| Haplotypes | 3 | 2021 | 197 | 0.230 |
Why?
|
| Inflammation | 2 | 2023 | 729 | 0.230 |
Why?
|
| Rural Population | 2 | 2025 | 352 | 0.230 |
Why?
|
| Nerve Tissue Proteins | 3 | 2016 | 382 | 0.230 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2015 | 54 | 0.230 |
Why?
|
| Incidence | 7 | 2024 | 1054 | 0.220 |
Why?
|
| Delphi Technique | 1 | 2024 | 30 | 0.220 |
Why?
|
| Logistic Models | 8 | 2019 | 1001 | 0.220 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2015 | 90 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2002 | 979 | 0.210 |
Why?
|
| Life Style | 2 | 2020 | 326 | 0.200 |
Why?
|
| Adiposity | 1 | 2024 | 155 | 0.200 |
Why?
|
| Behavior Therapy | 1 | 2025 | 179 | 0.200 |
Why?
|
| Clinical Competence | 1 | 2024 | 154 | 0.200 |
Why?
|
| Membrane Proteins | 2 | 2019 | 548 | 0.200 |
Why?
|
| Dietary Supplements | 3 | 2017 | 208 | 0.200 |
Why?
|
| Environmental Exposure | 1 | 2025 | 247 | 0.200 |
Why?
|
| Students, Nursing | 1 | 2023 | 37 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 15 | 3 | 2018 | 10 | 0.190 |
Why?
|
| Alcohol Drinking | 2 | 2018 | 585 | 0.190 |
Why?
|
| Leadership | 1 | 2023 | 84 | 0.190 |
Why?
|
| Interferon-alpha | 1 | 2002 | 43 | 0.190 |
Why?
|
| Social Class | 1 | 2024 | 286 | 0.190 |
Why?
|
| Sleep | 1 | 2024 | 179 | 0.190 |
Why?
|
| Weight Gain | 2 | 2016 | 138 | 0.190 |
Why?
|
| Marijuana Abuse | 1 | 2023 | 93 | 0.190 |
Why?
|
| Advisory Committees | 1 | 2022 | 34 | 0.180 |
Why?
|
| Registries | 3 | 2022 | 431 | 0.180 |
Why?
|
| Dementia | 1 | 2023 | 155 | 0.180 |
Why?
|
| Cultural Competency | 1 | 2022 | 137 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2021 | 20 | 0.180 |
Why?
|
| Referral and Consultation | 2 | 2020 | 141 | 0.170 |
Why?
|
| Melanoma | 1 | 2002 | 109 | 0.170 |
Why?
|
| Sick Leave | 1 | 2020 | 3 | 0.170 |
Why?
|
| Patient Compliance | 2 | 2015 | 225 | 0.170 |
Why?
|
| Absenteeism | 1 | 2020 | 14 | 0.170 |
Why?
|
| Trust | 2 | 2019 | 157 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 933 | 0.170 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2020 | 15 | 0.170 |
Why?
|
| Unemployment | 1 | 2020 | 27 | 0.170 |
Why?
|
| Body Height | 1 | 2021 | 53 | 0.170 |
Why?
|
| Athletes | 1 | 2021 | 61 | 0.170 |
Why?
|
| Activities of Daily Living | 2 | 2015 | 136 | 0.170 |
Why?
|
| Lung | 3 | 2022 | 484 | 0.170 |
Why?
|
| Adaptation, Physiological | 1 | 2021 | 135 | 0.160 |
Why?
|
| Patient Education as Topic | 3 | 2020 | 234 | 0.160 |
Why?
|
| Critical Pathways | 1 | 2020 | 18 | 0.160 |
Why?
|
| Housing | 1 | 2020 | 68 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2019 | 10 | 0.160 |
Why?
|
| RNA Polymerase III | 1 | 2019 | 6 | 0.160 |
Why?
|
| Parity | 2 | 2018 | 60 | 0.160 |
Why?
|
| Quantitative Trait Loci | 2 | 2019 | 88 | 0.160 |
Why?
|
| Metabolic Diseases | 1 | 2020 | 38 | 0.160 |
Why?
|
| Mental Health | 1 | 2004 | 363 | 0.160 |
Why?
|
| Organ Specificity | 1 | 2019 | 141 | 0.160 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 8 | 0.150 |
Why?
|
| Colorectal Neoplasms | 1 | 2025 | 502 | 0.150 |
Why?
|
| Lod Score | 3 | 2021 | 13 | 0.150 |
Why?
|
| Glucuronosyltransferase | 1 | 2019 | 29 | 0.150 |
Why?
|
| Mutation | 3 | 2022 | 1169 | 0.150 |
Why?
|
| Phenotype | 3 | 2016 | 774 | 0.150 |
Why?
|
| Research Personnel | 2 | 2021 | 191 | 0.150 |
Why?
|
| Smoking Cessation | 2 | 2016 | 583 | 0.150 |
Why?
|
| Walking | 2 | 2021 | 85 | 0.150 |
Why?
|
| Health Personnel | 2 | 2019 | 262 | 0.150 |
Why?
|
| Perception | 1 | 2020 | 209 | 0.150 |
Why?
|
| Genital Diseases, Female | 1 | 2018 | 38 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 4 | 3 | 2019 | 7 | 0.140 |
Why?
|
| Research Design | 3 | 2024 | 370 | 0.140 |
Why?
|
| Receptors, Calcitriol | 1 | 2019 | 69 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2025 | 705 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 146 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 309 | 0.140 |
Why?
|
| Vitamin D | 2 | 2019 | 196 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2015 | 32 | 0.140 |
Why?
|
| Obesity | 4 | 2024 | 1131 | 0.140 |
Why?
|
| Europe | 4 | 2021 | 114 | 0.140 |
Why?
|
| BRCA2 Protein | 2 | 2015 | 50 | 0.140 |
Why?
|
| Health Behavior | 1 | 2022 | 568 | 0.140 |
Why?
|
| Age Factors | 4 | 2020 | 1139 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 959 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2023 | 467 | 0.140 |
Why?
|
| Sterilization, Tubal | 1 | 2017 | 6 | 0.140 |
Why?
|
| Socioeconomic Factors | 4 | 2025 | 1221 | 0.140 |
Why?
|
| Mass Screening | 1 | 2022 | 531 | 0.140 |
Why?
|
| Community Health Services | 2 | 2019 | 207 | 0.140 |
Why?
|
| Resilience, Psychological | 1 | 2019 | 89 | 0.140 |
Why?
|
| Menstruation | 1 | 2017 | 11 | 0.130 |
Why?
|
| Residence Characteristics | 2 | 2021 | 359 | 0.130 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 57 | 0.130 |
Why?
|
| Ovulation | 1 | 2017 | 21 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 508 | 0.130 |
Why?
|
| Evidence-Based Medicine | 3 | 2019 | 107 | 0.130 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 228 | 0.130 |
Why?
|
| Pedigree | 4 | 2021 | 94 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 222 | 0.130 |
Why?
|
| Dairy Products | 1 | 2016 | 34 | 0.130 |
Why?
|
| Contraceptives, Oral | 1 | 2016 | 17 | 0.130 |
Why?
|
| Genotype | 2 | 2016 | 796 | 0.130 |
Why?
|
| X Chromosome Inactivation | 1 | 2016 | 10 | 0.130 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 23 | 0.130 |
Why?
|
| Powders | 1 | 2016 | 20 | 0.130 |
Why?
|
| Privacy | 1 | 2016 | 7 | 0.130 |
Why?
|
| Vital Capacity | 1 | 2016 | 44 | 0.130 |
Why?
|
| Spirometry | 1 | 2016 | 40 | 0.130 |
Why?
|
| Bioethical Issues | 1 | 2016 | 6 | 0.130 |
Why?
|
| Cultural Deprivation | 1 | 2016 | 3 | 0.120 |
Why?
|
| Respiratory Function Tests | 1 | 2016 | 61 | 0.120 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2016 | 20 | 0.120 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2016 | 24 | 0.120 |
Why?
|
| Forced Expiratory Volume | 1 | 2016 | 75 | 0.120 |
Why?
|
| Glycemic Index | 1 | 2015 | 10 | 0.120 |
Why?
|
| Calcium, Dietary | 1 | 2016 | 64 | 0.120 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 330 | 0.120 |
Why?
|
| Medical History Taking | 3 | 2021 | 37 | 0.120 |
Why?
|
| Protective Agents | 1 | 2016 | 26 | 0.120 |
Why?
|
| Dietary Carbohydrates | 1 | 2015 | 34 | 0.120 |
Why?
|
| Health Services, Indigenous | 1 | 2016 | 33 | 0.120 |
Why?
|
| Analgesics | 1 | 2016 | 55 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 438 | 0.110 |
Why?
|
| Selenium | 1 | 2017 | 150 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 246 | 0.110 |
Why?
|
| Breast Feeding | 1 | 2016 | 123 | 0.110 |
Why?
|
| Attitude to Health | 1 | 2017 | 336 | 0.110 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 79 | 0.110 |
Why?
|
| Feedback | 1 | 2015 | 55 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 61 | 0.110 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 163 | 0.110 |
Why?
|
| Chromosomes, Human | 1 | 2014 | 37 | 0.110 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2014 | 45 | 0.110 |
Why?
|
| Selection, Genetic | 1 | 2014 | 75 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2014 | 101 | 0.110 |
Why?
|
| Genetics, Population | 1 | 2014 | 118 | 0.110 |
Why?
|
| Genetic Loci | 1 | 2014 | 102 | 0.110 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 1068 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 200 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 249 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2009 | 708 | 0.100 |
Why?
|
| Hypertension | 1 | 2020 | 823 | 0.100 |
Why?
|
| Educational Status | 1 | 2014 | 335 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 222 | 0.100 |
Why?
|
| American Cancer Society | 1 | 2012 | 2 | 0.100 |
Why?
|
| Hip Joint | 1 | 2012 | 14 | 0.090 |
Why?
|
| Single-Blind Method | 1 | 2011 | 53 | 0.090 |
Why?
|
| Cytokines | 1 | 2015 | 661 | 0.090 |
Why?
|
| Comorbidity | 3 | 2020 | 725 | 0.090 |
Why?
|
| Public Health | 1 | 2016 | 405 | 0.090 |
Why?
|
| Age Distribution | 1 | 2012 | 249 | 0.090 |
Why?
|
| Survival Rate | 2 | 2012 | 353 | 0.090 |
Why?
|
| Nutritional Status | 1 | 2012 | 115 | 0.090 |
Why?
|
| Body Weights and Measures | 1 | 2011 | 25 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 137 | 0.090 |
Why?
|
| Age of Onset | 2 | 2024 | 115 | 0.090 |
Why?
|
| Adaptation, Psychological | 2 | 2016 | 410 | 0.090 |
Why?
|
| Risk | 3 | 2016 | 289 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 25 | 0.080 |
Why?
|
| Faculty | 2 | 2021 | 105 | 0.080 |
Why?
|
| Population Surveillance | 3 | 2016 | 245 | 0.080 |
Why?
|
| Bone Remodeling | 1 | 2010 | 23 | 0.080 |
Why?
|
| Mentors | 2 | 2021 | 143 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2022 | 362 | 0.080 |
Why?
|
| Nursing Assessment | 1 | 2009 | 6 | 0.080 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 74 | 0.080 |
Why?
|
| Child | 3 | 2025 | 3381 | 0.080 |
Why?
|
| Cognition | 2 | 2023 | 458 | 0.070 |
Why?
|
| Body Composition | 1 | 2009 | 160 | 0.070 |
Why?
|
| Nursing Evaluation Research | 1 | 2008 | 11 | 0.070 |
Why?
|
| Nurse's Role | 1 | 2008 | 35 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 1051 | 0.070 |
Why?
|
| Valerates | 1 | 2008 | 1 | 0.070 |
Why?
|
| Cachexia | 1 | 2008 | 4 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3077 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2009 | 180 | 0.070 |
Why?
|
| Alcoholic Beverages | 2 | 2018 | 16 | 0.070 |
Why?
|
| Glutamine | 1 | 2008 | 36 | 0.070 |
Why?
|
| Forecasting | 1 | 2008 | 136 | 0.070 |
Why?
|
| Arginine | 1 | 2008 | 75 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 154 | 0.070 |
Why?
|
| Decision Making | 2 | 2020 | 242 | 0.060 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2007 | 60 | 0.060 |
Why?
|
| Algorithms | 1 | 2009 | 508 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 1020 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2021 | 845 | 0.060 |
Why?
|
| Minority Groups | 2 | 2021 | 663 | 0.060 |
Why?
|
| North America | 2 | 2017 | 85 | 0.060 |
Why?
|
| Asia | 2 | 2017 | 99 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 638 | 0.060 |
Why?
|
| Genes, BRCA2 | 2 | 2016 | 12 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2025 | 57 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 209 | 0.060 |
Why?
|
| Adolescent | 3 | 2023 | 5950 | 0.060 |
Why?
|
| Nutrition Surveys | 2 | 2016 | 263 | 0.060 |
Why?
|
| Health Status | 1 | 2008 | 432 | 0.060 |
Why?
|
| Consensus | 1 | 2024 | 53 | 0.050 |
Why?
|
| Prevalence | 2 | 2020 | 1597 | 0.050 |
Why?
|
| Australia | 1 | 2024 | 95 | 0.050 |
Why?
|
| Alleles | 2 | 2016 | 352 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2014 | 203 | 0.050 |
Why?
|
| Physical Education and Training | 1 | 2023 | 28 | 0.050 |
Why?
|
| Immunization | 1 | 2023 | 93 | 0.050 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2024 | 70 | 0.050 |
Why?
|
| Memory, Short-Term | 1 | 2023 | 56 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2023 | 106 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2002 | 19 | 0.050 |
Why?
|
| Attitude | 1 | 2023 | 108 | 0.050 |
Why?
|
| Social Behavior | 1 | 2004 | 160 | 0.050 |
Why?
|
| School Health Services | 1 | 2023 | 89 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2016 | 393 | 0.050 |
Why?
|
| Environment Design | 1 | 2021 | 31 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2021 | 90 | 0.040 |
Why?
|
| Africa | 1 | 2021 | 81 | 0.040 |
Why?
|
| Health Policy | 1 | 2023 | 184 | 0.040 |
Why?
|
| Schools, Medical | 1 | 2023 | 208 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2021 | 198 | 0.040 |
Why?
|
| Schools | 1 | 2023 | 283 | 0.040 |
Why?
|
| Curriculum | 1 | 2023 | 311 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2002 | 574 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2019 | 7 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 2019 | 14 | 0.040 |
Why?
|
| Lymphedema | 1 | 2019 | 7 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 47 | 0.040 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2019 | 16 | 0.040 |
Why?
|
| Psychometrics | 1 | 2002 | 350 | 0.040 |
Why?
|
| Program Development | 1 | 2020 | 237 | 0.040 |
Why?
|
| Exercise Test | 1 | 2019 | 75 | 0.040 |
Why?
|
| Follistatin | 1 | 2019 | 28 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2019 | 78 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 37 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 77 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2018 | 8 | 0.040 |
Why?
|
| Ovarian Cysts | 1 | 2018 | 3 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 118 | 0.040 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2018 | 19 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2019 | 121 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2018 | 89 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2019 | 201 | 0.040 |
Why?
|
| Overweight | 1 | 2020 | 248 | 0.040 |
Why?
|
| Probability | 1 | 2018 | 82 | 0.030 |
Why?
|
| Uterine Neoplasms | 1 | 2018 | 51 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2019 | 137 | 0.030 |
Why?
|
| Leiomyoma | 1 | 2018 | 40 | 0.030 |
Why?
|
| Menarche | 1 | 2017 | 15 | 0.030 |
Why?
|
| Students | 1 | 2023 | 617 | 0.030 |
Why?
|
| Endometriosis | 1 | 2018 | 81 | 0.030 |
Why?
|
| Menopause | 1 | 2017 | 63 | 0.030 |
Why?
|
| Premenopause | 1 | 2017 | 109 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 928 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2023 | 2485 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 215 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2016 | 162 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 512 | 0.030 |
Why?
|
| Carcinoma, Large Cell | 1 | 2016 | 4 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 28 | 0.030 |
Why?
|
| Dietary Sucrose | 1 | 2015 | 17 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 157 | 0.030 |
Why?
|
| Point Mutation | 1 | 2015 | 98 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 2016 | 74 | 0.030 |
Why?
|
| Social Support | 1 | 2018 | 438 | 0.030 |
Why?
|
| SEER Program | 1 | 2015 | 157 | 0.030 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 107 | 0.030 |
Why?
|
| Brain | 1 | 2023 | 1452 | 0.030 |
Why?
|
| Poverty | 1 | 2018 | 395 | 0.030 |
Why?
|
| Genes, p16 | 1 | 2014 | 11 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2014 | 20 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 454 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 147 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2015 | 88 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 532 | 0.030 |
Why?
|
| DNA Primers | 1 | 2015 | 295 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2016 | 428 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 81 | 0.030 |
Why?
|
| Base Sequence | 1 | 2015 | 997 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 1058 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2014 | 299 | 0.020 |
Why?
|
| Pregnancy | 1 | 2018 | 1737 | 0.020 |
Why?
|
| Depression | 1 | 2019 | 837 | 0.020 |
Why?
|
| Prescriptions | 1 | 2012 | 20 | 0.020 |
Why?
|
| Anxiety | 1 | 2019 | 847 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1559 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 324 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 274 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 1848 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2010 | 61 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2014 | 501 | 0.020 |
Why?
|
| Plethysmography | 1 | 2008 | 6 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 41 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 95 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 113 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 233 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 305 | 0.020 |
Why?
|
| Markov Chains | 1 | 2007 | 42 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2007 | 66 | 0.020 |
Why?
|